PT - JOURNAL ARTICLE AU - Johanna Krüger AU - Julian Schubert AU - Josua Kegele AU - Audrey Labalme AU - Miaomiao Mao AU - Jacqueline Heighway AU - Guiscard Seebohm AU - Pu Yan AU - Mahmoud Koko AU - Kezban Aslan AU - Hande Caglayan AU - Bernhard J. Steinhoff AU - Yvonne G. Weber AU - Pascale Keo-Kosal AU - Samuel F. Berkovic AU - Michael S. Hildebrand AU - Steven Petrou AU - Roland Krause AU - Patrick May AU - Gaetan Lesca AU - Snezana Maljevic AU - Holger Lerche TI - Loss-of-function variants in the <em>KCNQ5</em> gene are associated with genetic generalized epilepsies AID - 10.1101/2021.04.20.21255696 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.20.21255696 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.20.21255696.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.20.21255696.full AB - Objective De novo missense variants in KCNQ5, encoding the voltage-gated K+ channel KV7.5, have been described as a cause of developmental and epileptic encephalopathy (DEE) or intellectual disability (ID). We set out to identify disease-related KCNQ5 variants in genetic generalized epilepsy (GGE) and their underlying mechanisms.Methods 1292 families with GGE were studied by next-generation sequencing. Whole-cell patch-clamp recordings, biotinylation and phospholipid overlay assays were performed in mammalian cells combined with docking and homology modeling.Results We identified three deleterious heterozygous missense variants, one truncation and one splice site alteration in five independent families with GGE with predominant absence seizures, two variants were also associated with mild to moderate ID. All three missense variants displayed a strongly decreased current density indicating a loss-of-function (LOF). When mutant channels were co-expressed with wild-type (WT) KV7.5 or KV7.5 and KV7.3 channels, three variants also revealed a significant dominant-negative effect on WT channels. Other gating parameters were unchanged. Biotinylation assays indicated a normal surface expression of the variants. The p.Arg359Cys variant altered PI(4,5)P2- interaction, presumably in the non-conducting preopen-closed state.Interpretation Our study indicates that specific deleterious KCNQ5 variants are associated with GGE, partially combined with mild to moderate ID. The disease mechanism is a LOF partially with dominant-negative effects through functional, rather than trafficking deficits. LOF of KV7.5 channels will reduce the M-current, likely resulting in increased excitability of KV7.5- expressing neurons. Further studies on a network level are necessary to understand which circuits are affected and how the variants induce generalized seizures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Research Unit FOR-2715, funded by the German Research Foundation (DFG) and the Fond Nationale de la Recherche (FNR) in Luxembourg (grants Le1030/16-1 to HL, INTER/DFG/17/11583046 to RK/PM, and We4896/4-1 to YGW), by the German Federal Ministry for Education and Research (BMBF, Treat-ION, 01GM1907 to HL, YGW, RK, PM) and by the European Science Foundation (EuroEPINOMICS-CoGIE project, grants from national funding agencies: DFG Le1030/11-1/2 to HL, FNR INTER/ESF/10/02/CoGIE to Rudi Balling/RK/PM). The foundation ′no epilep′ funded patient recruitment (to HL). Epi25 was supported by the National Human Genome Research Institute (NHGRI) grants UM1 HG008895 and 5U01HG009088-02, and the Stanley Center for Psychiatric Research at the Broad Institute. The Epi4K study was supported by a National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) grant (ID: U01NS077367). We acknowledge the contribution of the HPC facilities of the University of Luxembourg (http://hpc.uni.lu) for computational support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Board of the Medical Faculty of the University of Tuebingen. Ethics Board of the University of Lyon. Ethics Board of the University of Melbourne.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available upon request.